How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "6326"
  ["article_id"]=>
  string(4) "6326"
  [1]=>
  string(72) "Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal"
  ["article_title"]=>
  string(72) "Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal"
  [2]=>
  string(150) "As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contingent payments of up to $1bn based"
  ["short_description"]=>
  string(150) "As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contingent payments of up to $1bn based"
  [3]=>
  string(527) "
As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contingent payments of up to $1bn based on 
&#nl
The post Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(527) "
As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contingent payments of up to $1bn based on 
&#nl
The post Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(82) "https://www.pharmaceutical-business-review.com/news/roche-promedior-biotechnology/"
  ["blog_url"]=>
  string(82) "https://www.pharmaceutical-business-review.com/news/roche-promedior-biotechnology/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-19 16:35:09"
  ["create_at"]=>
  string(19) "2019-11-19 16:35:09"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Roche to buy clinical-stage biotechnology firm Promedior in $1.39bn deal

As per terms of the merger deal, Promedior will secure an upfront cash payment of $390m, as well as additional contin

array(40) {
  [0]=>
  string(4) "6360"
  ["article_id"]=>
  string(4) "6360"
  [1]=>
  string(169) "Fresenius Kabi starts United for Clinical Nutrition initiative in Europe with first-of-its-kind clinical study assessing critically ill patients in 11 European countries"
  ["article_title"]=>
  string(169) "Fresenius Kabi starts United for Clinical Nutrition initiative in Europe with first-of-its-kind clinical study assessing critically ill patients in 11 European countries"
  [2]=>
  string(150) "BAD HOMBURG, GERMANY – [November 18, 2019] The first patients are about to be enrolled in the EuroPN survey, a clinical study that will assess t"
  ["short_description"]=>
  string(150) "BAD HOMBURG, GERMANY – [November 18, 2019] The first patients are about to be enrolled in the EuroPN survey, a clinical study that will assess t"
  [3]=>
  string(523) "BAD HOMBURG, GERMANY – [November 18, 2019] The first patients are about to be enrolled in the EuroPN survey, a clinical study that will assess the nutritional balance and focus on functional outcomes of critically ill patients in about 100 hospitals across 11 European countries. The survey is an important scientific project by United for Clinical Nutrition (UFCN), a global initiative that strives to fight hospital malnutrition and its detrimental effects on patient outcomes. Healthcare...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(523) "BAD HOMBURG, GERMANY – [November 18, 2019] The first patients are about to be enrolled in the EuroPN survey, a clinical study that will assess the nutritional balance and focus on functional outcomes of critically ill patients in about 100 hospitals across 11 European countries. The survey is an important scientific project by United for Clinical Nutrition (UFCN), a global initiative that strives to fight hospital malnutrition and its detrimental effects on patient outcomes. Healthcare...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(105) "http://www.realwire.com/releases/Fresenius-Kabi-starts-United-for-Clinical-Nutrition-initiative-in-Europe"
  ["blog_url"]=>
  string(105) "http://www.realwire.com/releases/Fresenius-Kabi-starts-United-for-Clinical-Nutrition-initiative-in-Europe"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-19 16:36:06"
  ["create_at"]=>
  string(19) "2019-11-19 16:36:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Fresenius Kabi starts United for Clinical Nutrition initiative in Europe with first-of-its

BAD HOMBURG, GERMANY – [November 18, 2019] The first patients are about to be enrolled in the EuroPN survey, a cli

array(40) {
  [0]=>
  string(4) "6505"
  ["article_id"]=>
  string(4) "6505"
  [1]=>
  string(71) "Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC"
  ["article_title"]=>
  string(71) "Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC"
  [2]=>
  string(150) "The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC"
  ["short_description"]=>
  string(150) "The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC"
  [3]=>
  string(578) "
The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC, who did not receive prior systemic therapy. Data 
&#nl
The post Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(578) "
The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 501 patients with unresectable HCC, who did not receive prior systemic therapy. Data 
&#nl
The post Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/roche-tecentriq-avastin-imbrave150/"
  ["blog_url"]=>
  string(87) "https://www.pharmaceutical-business-review.com/news/roche-tecentriq-avastin-imbrave150/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Roche’s Tecentriq, Avastin combo improves OS in unresectable HCC

The late-stage trial called IMbrave150 evaluated the Tecentriq, Avastin combination in comparison with sorafenib in 5

array(40) {
  [0]=>
  string(4) "6506"
  ["article_id"]=>
  string(4) "6506"
  [1]=>
  string(112) "FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder"
  ["article_title"]=>
  string(112) "FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder"
  [2]=>
  string(155) "Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. Th"
  ["short_description"]=>
  string(155) "Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. Th"
  [3]=>
  string(717) "
Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges 
&#nl
The post FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(717) "
Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges 
&#nl
The post FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(157) "https://www.pharmaceutical-business-review.com/news/fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-for-major-depressive-disorder/"
  ["blog_url"]=>
  string(157) "https://www.pharmaceutical-business-review.com/news/fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-for-major-depressive-disorder/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for maj

Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient develop

array(40) {
  [0]=>
  string(4) "6507"
  ["article_id"]=>
  string(4) "6507"
  [1]=>
  string(120) "SOLIRIS receives approval in Japan for the prevention of relapse in patients with neuromyelitis optica spectrum disorder"
  ["article_title"]=>
  string(120) "SOLIRIS receives approval in Japan for the prevention of relapse in patients with neuromyelitis optica spectrum disorder"
  [2]=>
  string(154) "“We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredict"
  ["short_description"]=>
  string(154) "“We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredict"
  [3]=>
  string(711) "
“We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease,” said John Orloff, M.D., 
&#nl
The post SOLIRIS receives approval in Japan for the prevention of relapse in patients with neuromyelitis optica spectrum disorder appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(711) "
“We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suffering from this complex and unpredictable disease,” said John Orloff, M.D., 
&#nl
The post SOLIRIS receives approval in Japan for the prevention of relapse in patients with neuromyelitis optica spectrum disorder appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(173) "https://www.pharmaceutical-business-review.com/news/soliris-receives-approval-in-japan-for-the-prevention-of-relapse-in-patients-with-neuromyelitis-optica-spectrum-disorder/"
  ["blog_url"]=>
  string(173) "https://www.pharmaceutical-business-review.com/news/soliris-receives-approval-in-japan-for-the-prevention-of-relapse-in-patients-with-neuromyelitis-optica-spectrum-disorder/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

SOLIRIS receives approval in Japan for the prevention of relapse in patients with neuromye

“We are pleased that the Japanese health authorities have approved SOLIRIS as a new treatment for patients suff

array(40) {
  [0]=>
  string(4) "6508"
  ["article_id"]=>
  string(4) "6508"
  [1]=>
  string(48) "Novartis to buy The Medicines Company for $9.7bn"
  ["article_title"]=>
  string(48) "Novartis to buy The Medicines Company for $9.7bn"
  [2]=>
  string(150) "As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share in cash. Headquartered in Parsip"
  ["short_description"]=>
  string(150) "As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share in cash. Headquartered in Parsip"
  [3]=>
  string(529) "
As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share in cash. Headquartered in Parsippany, New Jersey, The 
&#nl
The post Novartis to buy The Medicines Company for $9.7bn appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(529) "
As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share in cash. Headquartered in Parsippany, New Jersey, The 
&#nl
The post Novartis to buy The Medicines Company for $9.7bn appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/deals/novartis-medicines-company-deal/"
  ["blog_url"]=>
  string(90) "https://www.pharmaceutical-business-review.com/news/deals/novartis-medicines-company-deal/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Novartis to buy The Medicines Company for $9.7bn

As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share

array(40) {
  [0]=>
  string(4) "6509"
  ["article_id"]=>
  string(4) "6509"
  [1]=>
  string(132) "Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer"
  ["article_title"]=>
  string(132) "Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer"
  [2]=>
  string(157) "Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Flow Electroporation® technology and Ex"
  ["short_description"]=>
  string(157) "Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Flow Electroporation® technology and Ex"
  [3]=>
  string(747) "
Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop up to five engineered 
&#nl
The post Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(747) "
Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop up to five engineered 
&#nl
The post Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineered hematopoietic stem cells to treat cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(185) "https://www.pharmaceutical-business-review.com/news/vor-biopharma-and-maxcyte-announce-clinical-and-commercial-licence-agreement-for-engineered-hematopoietic-stem-cells-to-treat-cancer/"
  ["blog_url"]=>
  string(185) "https://www.pharmaceutical-business-review.com/news/vor-biopharma-and-maxcyte-announce-clinical-and-commercial-licence-agreement-for-engineered-hematopoietic-stem-cells-to-treat-cancer/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Vor Biopharma and MaxCyte announce clinical and commercial licence agreement for engineere

Under the terms of the agreement, Vor obtains non-exclusive clinical and commercial use rights to MaxCyte’s Fl

array(40) {
  [0]=>
  string(4) "6510"
  ["article_id"]=>
  string(4) "6510"
  [1]=>
  string(75) "ViiV Healthcare, NIH collaborate on investigational  bNAb for HIV treatment"
  ["article_title"]=>
  string(75) "ViiV Healthcare, NIH collaborate on investigational  bNAb for HIV treatment"
  [2]=>
  string(150) "Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells. N6LS is an antiv"
  ["short_description"]=>
  string(150) "Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells. N6LS is an antiv"
  [3]=>
  string(594) "
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells. N6LS is an antiviral bNAb that works by 
&#nl
The post ViiV Healthcare, NIH collaborate on investigational  bNAb for HIV treatment appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(594) "
Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells. N6LS is an antiviral bNAb that works by 
&#nl
The post ViiV Healthcare, NIH collaborate on investigational  bNAb for HIV treatment appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(126) "https://www.pharmaceutical-business-review.com/news/viiv-healthcare-nih-collaborate-on-investigational-bnab-for-hiv-treatment/"
  ["blog_url"]=>
  string(126) "https://www.pharmaceutical-business-review.com/news/viiv-healthcare-nih-collaborate-on-investigational-bnab-for-hiv-treatment/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ViiV Healthcare, NIH collaborate on investigational bNAb for HIV treatment

Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV int

array(40) {
  [0]=>
  string(4) "6511"
  ["article_id"]=>
  string(4) "6511"
  [1]=>
  string(72) "FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers"
  ["article_title"]=>
  string(72) "FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers"
  [2]=>
  string(155) "Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FD"
  ["short_description"]=>
  string(155) "Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FD"
  [3]=>
  string(557) "
Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from 
&#nl
The post FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(557) "
Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from 
&#nl
The post FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/fda-astrazeneca-calquence/"
  ["blog_url"]=>
  string(78) "https://www.pharmaceutical-business-review.com/news/fda-astrazeneca-calquence/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA approves AstraZeneca’s Calquence to treat lymphocytic cancers

Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently 

array(40) {
  [0]=>
  string(4) "6512"
  ["article_id"]=>
  string(4) "6512"
  [1]=>
  string(102) "EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable recurrent HNSCC"
  ["article_title"]=>
  string(102) "EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable recurrent HNSCC"
  [2]=>
  string(150) "This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with car"
  ["short_description"]=>
  string(150) "This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with car"
  [3]=>
  string(665) "
This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), demonstrated 
&#nl
The post EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable recurrent HNSCC appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(665) "
This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), demonstrated 
&#nl
The post EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable recurrent HNSCC appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(147) "https://www.pharmaceutical-business-review.com/news/ec-approves-two-new-regimens-of-mercks-keytruda-for-metastatic-or-unresectable-recurrent-hnscc/"
  ["blog_url"]=>
  string(147) "https://www.pharmaceutical-business-review.com/news/ec-approves-two-new-regimens-of-mercks-keytruda-for-metastatic-or-unresectable-recurrent-hnscc/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

EC approves two new regimens of Merck’s KEYTRUDA for metastatic or unresectable rec

This approval is based on findings from the pivotal Phase 3 KEYNOTE-048 trial, in which KEYTRUDA, compared with stand

array(40) {
  [0]=>
  string(4) "6513"
  ["article_id"]=>
  string(4) "6513"
  [1]=>
  string(48) "Alnylam announces approval of GIVLAARI by US FDA"
  ["article_title"]=>
  string(48) "Alnylam announces approval of GIVLAARI by US FDA"
  [2]=>
  string(150) "AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic ma"
  ["short_description"]=>
  string(150) "AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic ma"
  [3]=>
  string(587) "
AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of 
&#nl
The post Alnylam announces approval of GIVLAARI by US FDA appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(587) "
AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of 
&#nl
The post Alnylam announces approval of GIVLAARI by US FDA appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(101) "https://www.pharmaceutical-business-review.com/news/alnylam-announces-approval-of-givlaari-by-us-fda/"
  ["blog_url"]=>
  string(101) "https://www.pharmaceutical-business-review.com/news/alnylam-announces-approval-of-givlaari-by-us-fda/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Alnylam announces approval of GIVLAARI by US FDA

AHP is a family of ultra-rare, genetic diseases characterized by debilitating, potentially life-threatening attacks a

array(40) {
  [0]=>
  string(4) "6514"
  ["article_id"]=>
  string(4) "6514"
  [1]=>
  string(78) "Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene"
  ["article_title"]=>
  string(78) "Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene"
  [2]=>
  string(150) "With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.0"
  ["short_description"]=>
  string(150) "With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.0"
  [3]=>
  string(556) "
With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.00 share of BMS common stock 
&#nl
The post Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(556) "
With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.00 share of BMS common stock 
&#nl
The post Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/bristol-myers-squibb-celgene/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/bristol-myers-squibb-celgene/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-26 10:21:37"
  ["create_at"]=>
  string(19) "2019-11-26 10:21:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareho